Medical information reviewed by NP Bate, Ed.S. • Last reviewed: 2026-08-08 • Not a substitute for professional care.
Oral Interventions for Floaters: What the Evidence Shows
For decades, the only advice for floaters was “learn to live with it.” Two studies in the last five years challenged that assumption. Here is the full picture, no hype, no corporate filter.
Bottom line up front: neither product is FDA-approved for floaters. Both studies are early, small, and have limitations. But they are the best human data we have on oral floater interventions, and the results are stronger than anything previously published in this space.
1. VitroCap N, Micronutrient Formulation
A targeted oral supplement designed specifically for vitreous degeneration. It contains: L-lysine 125 mg, vitamin C 40 mg, Vitis vinifera extract 26.3 mg, zinc 5 mg, and Citrus aurantium 100 mg.
The Study
- Ankamah E, Green-Gomez M, Roche W, et al. TVST 2021;10(12):19. doi: 10.1167/tvst.10.12.19
- Design: Double-blind, placebo-controlled RCT
- N = 61 patients with symptomatic vitreous floaters
- Duration: 6 months, 1 capsule/day
- Primary outcome: Floater Disturbance Questionnaire
- Secondary outcomes: BCVA, contrast sensitivity, quantitative vitreous opacity area
Results
- Subjective visual discomfort: P < 0.001 vs. placebo (P = 0.416)
- Vitreous opacity area: P < 0.001 decrease in active group vs. insignificant increase in placebo
- 76.9% of active-group completers showed objective opacity reduction vs. 28.6% in placebo
- Photopic functional contrast sensitivity (positive polarity): P = 0.047
- 66.6% of active group achieved desired therapeutic effect
What This Means
This is the first double-blind RCT to show that an oral supplement can reduce both the subjective burden of floaters and the objective opacity area measured by imaging. The effect size is large. The proposed mechanism is antioxidative and antiglycation activity against vitreous collagen aggregation and hyaluronan depolymerization.
How to Find It
The tested product is commercially available as VitroCap N. It is the closest match to the exact study protocol. Amazon links vary by region; search “VitroCap N” directly if the affiliate link below does not resolve.
Limitations
- Small sample (n=61); single center
- Patient-reported outcome measure was developed for this trial and has not been independently validated
- Authors disclosed a pending patent/royalty agreement with ebiga-VISION GmbH
- No vitreous biopsies to confirm intravitreal concentrations
- Not yet replicated in a larger multi-center trial
2. Bromelain + Papain + Ficin, Proteolytic Enzyme Mix
A mixture of fruit-derived proteases formulated to hydrolyze collagen fibrils and hyaluronic acid aggregates in the vitreous. Each capsule contained 190 mg bromelain, 95 mg papain, and 95 mg ficin, with enteric protection to survive gastric digestion.
The Study
- Takeuchi M, Shieh P-C, Horng C-T. Appl Sci 2020;10(17):5901. doi: 10.3390/app10175901
- Design: Prospective cohort with placebo arm + dose-response arms
- N = 280 patients with symptomatic vitreous opacities
- Duration: 3 months
- Outcome: Change in number of symptomatic vitreous opacities (SVO) by ophthalmoscopy/OCT
Results
- Single SVO group: 70% treatment success rate after 3 months
- Multiple SVOs group: 72.5% treatment success rate
- Dose-dependent response: 65.5% (1 capsule/day) → 70% (2 capsules/day) → 75.5% (3 capsules/day)
- Placebo group: no significant change
- No serious adverse events or discomfort reported
Mechanistic Support
A 2024 in vitro study from Heidelberg validated the enzymatic mechanism. Hammer et al. showed that hyaluronic acid depletion increases vitreous forward light scattering, and that bromelain partially reversed this increase in HA-depleted vitreous gels. This supports the hypothesis that oral proteolytic enzymes can reduce floater-related light scatter.
- Hammer M, Muuss M, Schickhardt S, et al. IOVS 2024;65(3):36. doi: 10.1167/iovs.65.3.36
- In vitro porcine vitreous model with hyaluronidase, collagenase, trypsin, and bromelain
- Bromelain partially reversed forward light scattering increase in HA-depleted vitreous
How to Find It
The exact study formulation is 190 mg bromelain + 95 mg papain + 95 mg ficin per capsule, taken 1–3 capsules daily. The study used an enteric-coated capsule to protect the enzymes from stomach acid. No single commercial product matches this exact spec, but the closest available options are:
- Enteric-coated bromelain + papain blends — search for “enteric coated bromelain papain” with ≥190 mg bromelain per serving
- Ficin-containing enzyme blends — rarer; some compounding pharmacies can formulate
- Multi-enzyme supplements — look for bromelain, papain, and ficin listed separately with gram-level dosing
Limitations
- Not double-blind; open-label design
- Published in a general engineering/applied sciences journal, not an ophthalmology journal
- No independent masked reading core
- Mechanism is inferred; intravitreal enzyme concentrations were not measured
- Single-site study in Taiwan; generalizability uncertain
3. Low-Dose Atropine 0.01%, Symptomatic Relief
A 2025 pilot study presented at ASRS tested whether low-dose atropine drops could reduce the perceived burden of floaters. The hypothesized mechanism is pupillary dilation: a wider pupil reduces the shadow cast by vitreous opacities onto the retina.
The Study
- Du J, Sabbagh O, Do BK, et al. J Vitreoretin Dis 2025;9(6):831-835. doi: 10.1177/24741264251364819
- Also presented at ASRS 43rd Annual Meeting, 2025.
- Design: Prospective cohort, off-label use
- N = 44 patients with symptomatic vitreous floaters
- Intervention: 0.01% atropine drops
- Outcome: NEI Visual Function Questionnaire (NEI-VFQ) before and after 1 week
Results
- Among 1-week completers: 59% “satisfied” or “very satisfied”
- Overall intent-to-treat: 30% satisfied/very satisfied; 25% would continue use
- Adverse events: worsened near vision (18%), worsened distance vision (18%), photophobia (18%)
- No effect of iris color, phakic status, or PVD status on satisfaction
What This Means
The effect size is modest and comes with optical side effects. But for patients who cannot or do not want surgery/laser, this is another low-risk option. The mechanism is symptomatic, not curative: larger pupil → smaller shadow from floaters.
How to Find It
This requires a prescription for compounded 0.01% atropine drops. It is off-label; most ophthalmologists will not prescribe it routinely. If your doctor is open to it, compounding pharmacies can prepare it.
Limitations
- Small sample; short follow-up (1 week)
- Open-label; subjective outcome only
- Not for acute PVD
- No objective floater reduction measured
4. Curcumin-Based Supplement After Nd:YAG Capsulotomy
A 2025 pilot study examined whether a curcumin-based supplement could reduce floaters and foreign-body sensation after Nd:YAG capsulotomy, a laser procedure sometimes followed by transient visual symptoms.
The Study
- Malandrini A et al., 2025; Vision
- Design: Pilot study
- Population: Post-Nd:YAG capsulotomy patients with symptomatic floaters
- Intervention: Curcumin-based supplement
Results
- Significant reduction in symptomatic vitreous floaters
- Reduced foreign-body sensation
- Improved overall visual quality
- Tolerated well; no safety signals reported
What This Means
Curcumin has anti-inflammatory and antioxidant properties, but this is a very early signal in a specific post-procedure population. It does not establish efficacy for de novo floaters without prior YAG capsulotomy.
How to Find It
Curcumin supplements with piperine or other bioavailability enhancers are widely available. Look for brands that test for heavy metals and use a patented delivery form.
Limitations
- Pilot only; small sample
- Post-procedure population; results may not generalize to all floater patients
- No comparison arm reported in the available summary
Side-by-Side
| VitroCap N | Enzyme Mix | |
|---|---|---|
| Study type | Double-blind RCT | Prospective cohort |
| Sample size | 61 | 280 |
| Duration | 6 months | 3 months |
| Primary outcome | Subjective discomfort + opacity area | SVO count by exam |
| Key strength | Gold-standard design; objective imaging | Largest N; dose-response curve |
| Key limitation | Small; patent conflict | Open-label; single journal |
| Commercial availability | Available as VitroCap N | Not a branded product; DIY capsule formulation |
The Honest Assessment
These studies are not proof that floater supplements work for everyone. But they are the first real human data suggesting that oral interventions can meaningfully reduce the visual burden of vitreous floaters. That is a genuine advance over the previous standard of “nothing you can do.”
Both studies are small by pharmaceutical standards. Neither is replicated. Both have design limitations. The commercial product behind the Ankamah study has a financial interest in the results. The Takeuchi study lacks blinding. These are facts, not disqualifiers, but they are reasons to be hopeful, not certain.
If you are suffering from floaters, these low-risk oral options may be worth discussing with your eye doctor. They are not replacements for observation, YAG laser, or vitrectomy when those are indicated. But for patients in the “watchful waiting” zone, they are the first evidence-based alternative to pure reassurance.
Back to Floaters & PVD